Company news
Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A (SZSE:002294) news
Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A news releases on 6ix. Latest, Apr 21, 2026: Shenzhen Salubris Pharmaceuticals : Revenue up 8.5%, net…
Press releases & updates
Shenzhen Salubris Pharmaceuticals : Revenue up 8.5%, net profit up 8.3%, innovative drug sales up 47% year-over-year
April 21, 2026
Shenzhen Salubris Pharmaceuticals Plans To Seek Hong Kong Listing
January 21, 2026
Shenzhen Salubris Pharmaceuticals Co: Q3 2025 saw 15.85% revenue growth and 30.19% net profit increase, led by new products
October 28, 2025
Shenzhen Salubris Pharmaceuticals Co: Net profit rose 6.10% on 4.32% revenue growth, led by new drugs and medical device expansion
August 20, 2025
Shenzhen Salubris Pharmaceuticals Co: Patented and new product growth offset generic drug declines, keeping Q1 profit stable
April 22, 2025
Shenzhen Salubris Pharmaceuticals Co: 2024 revenue rose 19.22% to ¥4.01B, net profit up 3.71%, with strong R&D and cash dividend
March 28, 2025
Shenzhen Salubris Pharmaceuticals Co: Revenue and net profit rose on strong innovative product growth and robust cash flow
October 21, 2024
Shenzhen Salubris Pharmaceuticals Co: Revenue up 21.28% and net profit up 1.92% on innovation-driven growth
August 26, 2024
Shenzhen Salubris Pharmaceuticals : Announces Investment and In-Licensing Agreement With MedAlliance to Bring Novel Cardiovascular Disease Therapy to China
May 21, 2018